Form 4: LifeMD Chief Innovation Officer Sells 85,000 Shares Under Pre-Arranged Plan

LifeMD, Inc.'s Chief Innovation Officer, Stefan Galluppi, sold 85,000 shares of common stock on June 13, 2025, as part of a pre-scheduled Rule 10b5-1 trading plan.

Summary

• Stefan Galluppi, Chief Innovation Officer of LifeMD, Inc. (LFMD), reported the sale of 85,000 shares of the company's common stock.
• The transaction occurred on June 13, 2025, at a weighted average price of $12.3842 per share.
• The shares were sold in multiple transactions with prices ranging from $12.32 to $12.4900.
• Following this transaction, Mr. Galluppi directly beneficially owns 80,449 shares of common stock.
• Additionally, Mr. Galluppi indirectly beneficially owns 1,644,800 shares through American Nutra Tech, LLC.
• The sale was conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The sale is a pre-planned transaction under a Rule 10b5-1 plan, which typically indicates a scheduled liquidity event rather than a reaction to new negative information, thus making the sentiment neutral despite being an insider sale.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale for diversification or liquidity purposes rather than a reaction to new negative company information.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market, potentially leading to minor shifts in investor sentiment.

Risks

• Potential negative market perception due to insider selling, although this is largely mitigated by the disclosure that the transaction was part of a Rule 10b5-1 plan.

Stakeholder Impact

• Shareholders may observe the insider sale, which could lead to minor shifts in sentiment, though the Rule 10b5-1 plan mitigates concerns about management confidence.

Key Dates

Keywords

LifeMD, LFMD, Stefan Galluppi, Chief Innovation Officer, Insider Trading, Form 4, Stock Sale, Rule 10b5-1, Executive Stock Transaction